New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
07:01 EDTMNKMallinckrodt NDA for PENNSAID approved by FDA
Mallinckrodt announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s). U.S. sales and marketing rights for PENNSAID 2% are licensed to Mallinckrodt by Nuvo Research Inc.
News For MNK From The Last 14 Days
Check below for free stories on MNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:30 EDTMNKCRT Capital to hold a conference
2nd Annual Investor Conference to be held in Greenwich, CT on September 16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use